Fig. 6From: Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialIncidence of new or worsening grade 3 or 4 a anemia, b thrombocytopenia, and c leukopenia over time. Anemia, thrombocytopenia, and leukopenia were based on hematologic laboratory abnormalities. (asterisk) Placebo arm data are only shown up to 6Â months because all patients randomized to placebo crossed over or discontinued within 3Â months of the primary analysisBack to article page